Geselecteerde datamodellen

U moet ingelogd zijn om meerdere datamodellen te selecteren en die te downloaden of te analyseren.

5 Zoekresultaten.
Relevantie Beoordeling Nieuwe eerst Oude eerst

Neurological Examination Week 38 Mepolizumab HES NCT00086658 - Neurological Examination Week 38

- 15-07-17 - 1 Formulier, 1 Itemgroep, 18 Data-elementen, 1 Taal
Itemgroep: Neurological Examination
Study part: Neurological Examination Week 38/ Early Withdrawal visit.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Neurological Examination Week 16 Mepolizumab HES NCT00086658 - Neurological Examination Week 16

- 12-07-17 - 1 Formulier, 1 Itemgroep, 18 Data-elementen, 1 Taal
Itemgroep: Neurological Examination
Study part: Neurological Examination Week 16. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Neurological Examination Week 8 Mepolizumab HES NCT00086658 - Neurological Examination Week 8

- 09-07-17 - 1 Formulier, 1 Itemgroep, 18 Data-elementen, 1 Taal
Itemgroep: Neurological Examination
Study part: Neurological Examination Week 8. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Neurological Examination Week 4 Mepolizumab HES NCT00086658 - Neurological Examination Week 4

- 11-06-17 - 1 Formulier, 1 Itemgroep, 18 Data-elementen, 1 Taal
Itemgroep: Neurological Examination
Study part: Neurological Examination Week 4. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Neurological Examination Day 1 Pre-Infusion Mepolizumab HES NCT00086658 - Neurological Examination Day 1 Pre-Infusion

- 11-06-17 - 1 Formulier, 1 Itemgroep, 18 Data-elementen, 1 Taal
Itemgroep: Neurological Examination
Study part: Neurological Examination Day 1 Pre-Infusion.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Contact

Gebruik dit formulier voor feedback, vragen en verbeteringsvoorstellen.

Velden gemarkeerd met een * zijn verplicht.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial